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1  | INTRODUC TION
Obstructive sleep apnoea (OSA) has a high prevalence in the gen-
eral population with serious and widespread health implications.1 
OSA is characterised by breathing cessations during sleep with si-
multaneous awakenings/arousals and reductions in arterial blood 
oxygen levels.2 In an adult Norwegian population, the prevalence 
was reported as 16% for mild OSA and 8% for moderate to severe 
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Background: There is lack of reliable and accurate methods to predict treatment out-
comes of oral appliance (OA) treatment. Acoustic pharyngometry (AP) is a non-inva-
sive technique to evaluate the volume and minimal cross-sectional area of the upper 
airway, which may prove useful to locate the optimal position of OAs.
Objective: This retrospective study aimed to evaluate the effect of applying AP to 
OA treatment of patients with obstructive sleep apnoea (OSA).
Methods: All patients (n = 244) treated with OAs following an AP protocol at two 
dental clinics between 2013 and 2018 were invited to participate. A total of 129 pa-
tients accepted the invitation, and 120 patients (75 men, 45 women) were included 
in the analyses. Mean baseline age, BMI and apnoea hypopnea index (AHI) were 
59.1 ± 0.9 years, 27.8 ± 0.4 and 21.9 ± 1.1, respectively. Mean follow-up time was 
318 ± 24 days.
Results: AHI at follow-up was 6.4 ± 0.7, resulting in a treatment success rate of 86.7% 
(≥50% reduction of baseline AHI). The number of failures (<50% reduction of baseline 
AHI) did not differ significantly among patients with mild, moderate and severe OSA. 
87.6% of the patients reported OA usage every night, and 95.5% reported > 5 hours 
usage per night, when worn.
Conclusion: The AP protocol applied seems to contribute to the excellent effect of 
OA treatment in this study. Further research on the application of AP in OA treat-
ment is necessary in order to clarify its possible beneficial contribution to improving 
OA therapy.
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OSA.3 However, a more recent study based on updated diagnostic 
criteria on a similarly aged Swiss population suggests even higher 
prevalence rates.4 Continuous positive airway pressure (CPAP) 
is the gold standard in OSA treatment, defined by criteria set by 
the American Association of Sleep Medicine (AASM),1 but the ad-
herence to CPAP is generally poor, and reported as an average of 
65.9% in a large meta-analysis.5 Consequently, development of 
effective second-line treatment options, such as oral appliance 
(OA) therapy, is crucial. In recent studies, excellent objective 
compliance with OA therapy has been reported.6,7 Evidence sug-
gests that OA treatment may be comparable to CPAP in improving 
health outcome, even in more severe OSA, as the greater usage of 
OA may compensate for its inferior efficacy compared to CPAP.8,9 
Objectively measured efficacy with OA treatment, that is reduc-
tions in apnoea hypopnea index (AHI) and oxygen desaturation 
index (ODI), will hardly ever reach that of CPAP. It would therefore 
be important to develop techniques in order to improve the effi-
cacy of OA treatment.
OA titration/mandibular positioning is in many cases a ‘trial and 
error’ procedure, where the objective effect of each titration has to 
be assessed through an overnight polysomnographic (PSG) or an am-
bulatory polygraphic (PG) examination.10 Aside from complex and 
costly approaches, there is a lack of reliable and accurate methods to 
predict treatment outcome of OA therapy.11 Maximum comfortable 
protrusion is often referred to as the gold standard for titration of 
OAs, and clinicians often resort to increased mandibular protrusion 
when there is a lack of effect of OA treatment. However, a system-
atic review investigating the effectiveness of different mandibular 
advancements of OAs found that titration of the mandible above 
50% of maximal protrusion did not significantly influence the suc-
cess rate of the treatment, as measured by the reduction of AHI.12 
A study investigating the minimal protrusion needed for sufficient 
effect of OA therapy concluded that a great proportion of the study 
sample showed sufficient AHI reduction with no protrusion at all.13 
Historically, clinicians have relied on subjective symptoms as a mea-
sure of the efficacy of OA treatment. However, the relationship 
between an objective measure of the severity and subjective symp-
toms of OSA, such as daytime sleepiness, may be overestimated.14 
A reduced effect of OA treatment often results in that the clinician 
increases the protrusion of the mandible by titrating the appliance, 
which may increase the risk of side effects,15 and which in turn could 
adversely affect the adherence to treatment.
The role of the vertical dimension in OA treatment remains un-
clear. Studies have shown that the vertical dimension of the appli-
ance does not significantly impact the efficacy of the treatment,16-18 
while another study found that increased vertical dimension in 
maximal comfortable protrusion might cause increased pharyngeal 
collapsibility during sleep.19 Nevertheless, the accepted gold stan-
dard for vertical dimension in OA treatment is to keep the vertical 
dimension as low as possible. Hence, the need for individualised 
mandibular advancement and vertical dimension of OA in order to 
optimise comfort and treatment efficacy seems obvious, and would 
be in accordance with recent consensus within the field of dental 
sleep medicine.20
1.1 | Acoustic pharyngometry
Acoustic pharyngometry (AP) is a non-invasive technique that uses 
sound wave reflections to supply information about the cross-
sectional area and volume of the upper airway, from the lips to the 
epiglottis.21,22 Information is graphically and instantly displayed as 
a curve representing the cross-sectional area (y-axis) along the first 
25 cm of the upper airway (x-axis) (Figure 1, Appendix 1). The total 
volume of the first 25 cm of the upper airway is depicted as the area 
under the curve for the sum of the cross-sectional areas, while the 
F I G U R E  1   Comparison between 
baseline OSA diagnosis mild (n = 38), 
moderate (n = 59) and severe OSA 
(n = 23), according to success criteria 
applied at follow-up after oral appliance 
treatment. Patients were only classified 
as one of the success criteria, being 
the lowest criteria possible; that is, if 
they achieved AHI < 10 and > 50% 
reduction of baseline AHI at follow-
up, the treatment would be classified 
as success criterion 2 and not success 
criterion 3
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minimal cross-sectional area indicates where the upper airway is at 
its narrowest point. Airway volume measurements obtained with AP 
have been validated against computed tomography and magnetic 
resonance imaging, with acceptable accuracy.23,24 The reproducibil-
ity of the AP registration technique has also been investigated.25,26 
A standard operating protocol for acoustic pharyngometry has been 
proposed for normal breathing, and the repeatability of the protocol 
has also been validated.22,25
The collapsibility, or propensity for collapse of the upper air-
way (which is quantified as pressure differences in the upper air-
way during inspiration under negative generated pressure), and the 
minimal cross-sectional area have been proposed to be predictors of 
the presence of moderate/severe OSA.27,28 Volume changes of the 
pharyngeal cavity, as measured with AP, during positive and nega-
tive pressure indicate upper airway collapsibility, with significantly 
greater differences shown in OSA patients.29 Independent of age, 
gender and neck size, objective anatomical assessment with AP dis-
criminates well between patients with mild versus moderate to se-
vere OSA in a clinical setting.30 In addition, it has been shown that 
the pharynx of OSA patients shows greater tendency to collapse (i.e. 
collapsibility) when exhaling slowly from total lung capacity to resid-
ual volume (modified Mueller manoeuvre) compared with non-OSA 
patients.31,32 The collapsibility generated by the modified Mueller 
manoeuvre has previously been shown to be reproducible with ac-
ceptable intra-class correlation (ICC).33 In regard to the foregoing, by 
using AP it should be possible to locate the position of the mandible 
that provides the lowest pharyngeal collapsibility and the largest 
minimal cross-sectional area in the upper airway during a modified 
Mueller manoeuvre. This information could be used to determine 
the optimal position of the mandible and the OA.
The aim of this study was to evaluate the use of AP in OA treat-
ment in patients with mild, moderate and severe OSA.
2  | METHODS
2.1 | Patients and diagnostic procedures
All patients (n = 244) referred to two dental clinics (125 to 
Tannhelsesenteret Lørenskog and 119 to Tannhelsesenteret 
Sogndal) for OA treatment between 2013 and 2018 were invited to 
participate in the study. The patients were treated according to AP 
protocol described in detail in Appendix 1. The treatment was per-
formed by one of two calibrated dentists. The calibration comprised 
training sessions before the introduction of the AP methodology in 
the clinic. The calibration between the two dentists encompassed 
how to locate the optimal position of the OA based on the AP meas-
ures. A total of 129 patients (men = 80, women = 49) accepted the 
invitation and were included in the study. The baseline diagnosis of 
OSA was performed by ear, nose and throat specialists at referring 
hospitals, using one of two PG type IV devices (Embletta® or Nox 
T3®). The criteria for mild OSA were AHI 5 - <15, for moderate OSA 
AHI 15 - <30, and for severe OSA AHI ≥ 30.1 The objective effect of 
the OA treatment was investigated through home sleep testing with 
a PG type III device (Apnealink PlusTM or Apnealink AirTM, ResMed 
Germany Inc), with scoring rules in accordance with the 2007 AASM 
guidelines.34 Two patients were excluded from the study because 
they were diagnosed using other scoring rules. A total of 7 patients 
were excluded from the study because they did not have an OSA 
diagnosis (AHI < 5 at baseline) and were treated with OAs on the 
indication of social snoring. The distribution of baseline diagnoses 
of the 120 patients finally included was the following: 38 patients 
mild OSA (32%), 59 moderate OSA (49%) and 23 with severe OSA 
(19%). A total of 111 patients (94%) had previously tried CPAP but 
were non-compliant, 5 (4%) had never tried CPAP, and 2 (2%) of the 
patients did manage CPAP treatment but were referred for OA treat-
ment for other reasons. Data describing previous CPAP compliance 
were missing for 2 patients.
2.2 | Treatment protocol
The operating protocol for AP measures and locating the acous-
tic optimal position (AOP) of the mandible for the positioning of 
the OAs is described in detail in Appendix 1. Jaw registration was 
conducted in the individually determined position deemed optimal 
by AOP for all patients. Subsequent to delivery and adjustment of 
the OA, patients were instructed to use their OA throughout every 
night. The treatment was at minimum controlled after 3 weeks and 
3 months. However, the majority of the patients were followed up 
for a longer time due to different follow-up protocol required by re-
ferring hospitals in the early treatment years. Some patients were 
controlled more frequently if their OA needed adjustment to im-
prove the effect of the treatment, or to handle compliance issues. 
PG registrations were performed at every follow-up control, using 
the same PG type III device every time. The final visit to the clinic 
when the objective effect of the OA treatment was evaluated by PG 
registration was registered as the follow-up date. Mean follow-up 
time for the included patients was 318 days (95% CI: 271-365 days).
The final follow-up visit involved answering questionnaires re-
garding experienced side effects of the treatment, compliance and 
usage, subjective impact of the treatment on quality of life (QoL), 
subjective quality of sleep, snoring, daytime sleepiness and Epworth 
Sleepiness Scale (ESS, only recorded at follow-up). The OA position 
was assessed with AP at each follow-up control. If a better AOP 
compared to the current position was located, the OA was titrated 
to the new position. If patients reported a substantial positive effect 
on snoring, daytime sleepiness or other subjective OSA symptoms, 
and the PG recording showed adequate objective effect on AHI 
(AHI < 5), the OA was not adjusted from the baseline AOP, regard-
less of the new AP registration. Two different OAs were used in this 
study, the Narval CCTM appliance (n = 88, 73%) and the Somnodent® 
Fusion (n = 32, 27%). The latter was used primarily in cases where 
the Narval appliance was not indicated due to retention issues or in 
cases where patients did not want the Narval appliance. None of the 
included patients used elastic bands on their OAs.
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2.3 | Success criteria
The success at the final PG follow-up of the OA treatment was di-
vided into three categories, according to Gjerde et al34 Patients were 
only classified according to one of the success criteria, being the 
lowest criteria possible; that is, if they achieved AHI < 10 and > 50% 
reduction of baseline AHI at follow-up, the treatment would be clas-
sified as success criterion 2 and not success criterion 3.
• Success criterion 1: AHI < 5.
• Success criterion 2: AHI < 10 and > 50% reduction of baseline AHI.
• Success criterion 3: ≥50% reduction of baseline AHI.
• Failure: <50% reduction of AHI from baseline.
2.4 | Statistical analyses
All statistical analyses were performed with Stata version 16.0 
(College Station). Logistic regression analysis was performed in order 
to investigate associations with the strictest treatment success cri-
terion 1 (AHI < 5) as the dependent variable. An identical logistic re-
gression analysis was performed applying success criterion 3 (≥50% 
reduction of baseline AHI) as the dependent variable. Selection of 
independent variables in the unadjusted regression model included 
all those that were deemed to hypothetically influence the outcome 
of the dependent variable. Unadjusted logistic regression analysis 
(crude estimate) was first performed. Subsequently, an adjusted lo-
gistic regression analysis was performed including the independent 
variables exhibiting P < .1 in unadjusted analysis, applying a stepwise 
forward conditional method. Adjusted odds ratios with P < .05 were 
considered statistically significant in the adjusted model.
Unadjusted linear regression analysis was performed to inves-
tigate associations between side effects and subjective reported 
compliance. P < .05 was considered statistically significant in the lin-
ear regression. Kruskal-Wallis test was used to analyse differences 
between baseline AHI in the three success groups and the failures. 
The Kruskal-Wallis test was supplemented with a Mann-Whitney U 
test to analyse significant differences using Bonferroni correction 
as Post hoc test, that is P < .017 and P < .008 for 3 and 4 groups, 
respectively, was considered statistically significant.
For the missing data analysis, linear regression analysis was 
performed to investigate differences in age, baseline BMI and AHI 
between the included respondents and the non-respondents in 
this study. Pearson's chi-squared test was performed to investigate 
differences in gender between respondents and non-respondents. 
P < .05 was considered statistically significant.
All data are presented as mean ± standard error of the mean.
2.5 | Ethics
The study was approved by the regional ethics committee of 
Western Norway, and informed written consent was obtained 
from all participants (protocol no: 2018/2121). The study was also 
approved by the Health and social services representative of the 
University of Bergen (protocol no: 2018/2121).
3  | RESULTS
A total of 120 patients (men = 75, women = 45) were included in the 
follow-up evaluation. At baseline, 16 patients (13.9%) were smok-
ers, 28 (24.4%) had hypertension, 8 (7.0%) had cardiovascular dis-
ease and 3 (2.6%) diabetes. Table 1 provides further baseline patient 
characteristics. The overall success rate based on criteria 1 to 3 was 
86.7%, and 81.7% based only on success criteria 1 to 2 (Figure 1). For 
all patients, mean AHI at follow-up was 6.4 ± 0.7, a reduction from 
a mean AHI of 21.9 ± 1.1 at baseline, which represents a mean per-
centage AHI reduction of 66.7% ± 3.8. Follow-up AHI in the three 
OSA baseline diagnoses of mild, moderate and severe, were 5.2, 5.6 
and 10.3, respectively. When comparing the follow-up AHI in the 
three OSA groups, the severe group had significantly higher AHI 
than the mild group (P = .01), but not so compared to the moderate 
group (P = .09) (Mann-Whitney U test). There were no significant 
differences among the three baseline diagnoses and the success cri-
teria recorded at follow-up (Kruskal-Wallis, P = .33).
Baseline AHI was significantly different among patients ob-
taining success criteria 1, 2, and 3 and the failures at follow-up 
(Kruskal-Wallis, P = .0001) (Figure 2). This difference was attributed 
to patients achieving success criterion 3 (≥50 reduction of baseline 
AHI) compared criterion 1 (AHI < 5) at follow-up (P = .006), i.e. sig-
nificantly higher baseline AHI in those who reached criterion 3 at fol-
low-up. Bivariate group comparisons between the other categories 
and baseline AHI revealed no significant differences when applying 
Bonferroni correction.
Mean ODI at follow-up was 6.7 ± 0.7, mean SaO2 was 
92.7% ± 0.1%, and mean percentage of time with SaO2 < 90% sat-
uration was 14.3% ± 2.0%. Mean ESS at follow-up was 6.1 ± 0.4.
As regards self-reported compliance at follow-up, 87.6% of the 
patients reported usage of their OA every night, and 95.5% re-
ported > 5 hours usage per night, when worn. Of the 87.6% that 
reported usage of their OA every night, 95.9% reported > 5 hours 
usage per night. Improved QoL at follow-up was reported by 88.4% 
and no change by 11.6%. None of the patients reported worsening 
of QoL. Excellent or adequate subjective effect on snoring was re-
ported by 81.2%, 78.2% on quality of sleep, and 75.7% on daytime 
sleepiness.
Regarding side effects, 14.9% of the patients responded in the 
affirmative to sounds/pain from the temporomandibular joints, 
17.5% to pain or tension from masticatory muscles, 9.7% headache, 
14.9% hypersalivation and 43.9% dry mouth. These figures do not 
necessarily represent the status at follow-up but reflect side effects 
occurring during the course of OA treatment, and were often di-
minishing in nature. Reported pain/tension in the masticatory mus-
cles correlated significantly with reduced compliance, inferred from 
how many nights per week the OA was used (P < .001, unadjusted 
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linear regression analysis). None of the other side effects showed 
any significant correlations with OA compliance. Interincisal dis-
tance with the OA in the AOP was 4 mm in 43.0% of the patients 
and > 4 mm for the remaining patients (57.0%). The distribution was 
6 mm (38.6%), 8 mm (14.0%), 10 mm (3.5%) and 12 mm (0.9%) inter-
incisal distance.
TA B L E  1   Baseline characteristics of included patients (n = 120)
Mean 95% CI SE Min, max
Demographic and clinical parameters
Age, y 59.1 57.4-60.9 0.9 31, 77
BMI 27.8 27.1-28.5 0.4 21, 38.8
Baseline AHI 21.9 19.6-24.2 1.1 5.4, 73.8
VOB, mm 3.0 2.7-3.3 0.2 0, 7
HOB, mm 2.9 2.5-3.2 0.2 -2, 8
Max interincisal distance, mm 47.1 46.1-48.1 0.5 34, 62
Max protrusion, mm 9.5 9.3-9.8 0.1 6, 13
Protrusion with OA, mm 6.7 6.3-7.1 0.2 1, 13
Percentage OA protrusion of max 71.4 67.4-75.5 0.2 12.5, 131.3
Interincisal distance with OA 5.6 5.3-5.9 0.2 4, 12
Total vertical elevation with OA 8.4 8.0-8.9 0.2 4, 16
Follow-up time, days 318.2 271.4-365.0 23.6 4, 158
AP parameters
Mean baseline total UA volume, cm3 34.5 32.3-36.7 1.1 5.1, 60.3
Mean collapse total UA volume, cm3 19.1 17.7-20.4 0.7 3.7, 39.5
Mean AOP total UA volume, cm3 26.4 24.4-28.4 1.0 6.9-58.8
Mean AOPti total UA volume, cm3 27.3 25.2-29.3 1.0 7.9, 52.3
Mean baseline min UA x-sect area, cm2 2.1 2.0-2.3 0.1 0.4, 7.5
Mean collapse min UA x-sect area, cm2 1.1 1.0-1.2 0.1 0.2-3.2
Mean AOP min UA x-sect area, cm2 1.6 1.5-1.8 0.1 0.5, 3.4
Mean AOPti min UA x-sect area, cm2 1.8 1.7-2.0 0.1 0.5, 4.3
Note: Abbreviations: SE, standard error, CI, confidence interval for variable, VOB, vertical overbite, HOB, horizontal overjet, OA, oral appliance, AP, 
acoustic pharyngometry, UA, upper airway, x-sect, cross-sectional, AOP, acoustic optimal position, AOPti, oral appliance in the final position after any 
necessary titration.
F I G U R E  2   Distribution of baseline 
and follow-up AHI between patients, 
grouped after success criteria obtained at 
follow-up
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3.1 | The failures
In total, 16 patients (13.3%) were classified as failures (<50% reduc-
tion of AHI from baseline). The failures had a mean baseline AHI of 
19.5 ± 2.6 and a mean AHI of 19.8 ± 3.3 at follow-up. In the ad-
justed logistic regression model, reported hypertension and smaller 
increase in total vertical elevation (overbite + vertical thickness of 
OA) were predictors of failure (Table 2). The mean total increases of 
vertical dimension with the OA were 6.6 ± 0.5 mm (CI: 5.6-7.7 mm) 
and 8.7 ± 0.3 mm (CI: 8.2-9.2 mm) in the failure group and the three 
success groups combined, respectively.
None of the variables commonly reported to be associated with 
success of OA treatment, such as gender, age and amount of protru-
sion, turned out to be significant predictors. Moreover, type of OA, 
subjectively reported compliance, or any of the AP measures were 
not significantly associated with failure of OA treatment (data not 
shown in tables).
Three patients showed higher AHI with OA compared to baseline 
AHI. In those patients, a new PG recording was performed without 
the OA and the results showed an aggravation of the OSA compared 
to that at the referral time. Still, in those three patients, we used the 
original baseline diagnosis and AHI in the analyses, and all of them 
consequently became treatment failures.
3.2 | Acoustic pharyngometry results
Descriptive data for AP measurements are shown in Table 1. No 
adjustments (protrusive titration) of the OA were needed in 18 
(15.0%) of the patients, while 72 (60.0%) needed a few adjustments, 
and 23 (19.2%) needed several adjustments. OAs were adjusted if: 
(a) objective efficacy was suboptimal (AHI > 5) and AP measures 
displayed a new AOP; (b) a gradual titration towards AOP was indi-
cated due to side effects; (c) patients experienced lack of retention 
of their OAs; or (d) the OA caused ulcerations and was adjusted in 
order to relieve the ulcerated area. Hence, how many of the OAs 
that needed titration exclusively to optimise objective efficacy 
was not recorded. For 7 patients (5.8%), new OAs were fabricated 
either due to lack of retention, suboptimal efficacy and AOP with 
a different vertical dimension, or due to lack of compliance with 
the current type of OA.
The percentage decrease in total upper airway volume from the 
baseline registration (functional residual volume, mean total vol-
ume 34.5 cm3) compared to the collapse registration (residual vol-
ume generated by modified Mueller manoeuvre, mean total volume 
19.1 cm3) correlated significantly with higher baseline AHI (linear re-
gression, P < .05). Hence, patients demonstrating a more collapsible 
airway also had a more severe OSA diagnosis at baseline.
In the unadjusted logistic regression analysis, several variables 
were significantly correlated with achieving the strictest success cri-
terion at follow-up (AHI < 5). However, in the adjusted model only 
reported absence of hypertension, lower BMI and greater AP total 
volume maintained during collapse registration at baseline were sig-
nificantly correlated with achieving success criterion 1 (AHI < 5) at 
follow-up (OR 2.90, OR 0.88, and OR 1.07, respectively) (Table 3).
Unadjusted linear regression analysis showed no significant cor-
relations between AHI at follow-up and subjective reported out-
come variables, such as ESS, subjective reported compliance, change 
in QoL, daytime somnolence, snoring and perceived quality of sleep 
(data not shown in tables).
Reference category
Unadjusted Adjusted
OR 95% CI P OR 95% CI P
AHI baseline 0.98 0.93-1.03 NS - - -
BMI 1.17 1.03-1.34 ** - - NS
Gender 1.00 0.34-2.97 NS - - -
Age 1.05 0.99-1.11 * - - NS
No hypertension 0.30 0.10-0.93 ** 0.25 0.07-0.86 **
No CHD 0.21 0.04-0.99 ** - - NS
Total vertical elevation 0.68 0.52-0.89 *** 0.64 0.48-0.87 ***
No diabetes 0.29 0.02-3.36 NS - - -
HOB 0.89 0.65-1.21 NS - - -
% of max protrusion 0.96 0.07-14.00 NS - - -
Type of OA 1.63 0.57-4.61 NS - - -
All AP measures NS - - -
Note: Abbreviations: OR, odds ratio, CI, confidence interval for OR, CHD, coronary heart disease, 
OA, oral appliance, VOB, vertical overbite, HOB, horizontal overjet, AP, acoustic pharyngometry.
Prob > chi2 = 0.0005; Pseudo R2 = 0.182.
****P ≤ .001; ***.001 < P ≤ .01; **.01 < P ≤ .05; *.05 < P ≤ .1. 
TA B L E  2   Logistic regression model 
for the odds of failure of OA treatment 
(<50% reduction of AHI from baseline) as 
dependent variable for the included 120 
patients in the study. Dependent variable 
dichotomised as 0 = ≥50% reduction of 
AHI from baseline, 1 = <50% reduction of 
AHI from baseline
     |  7OPSAHL et AL.
3.3 | Missing data analysis
Of the total 244 patients, 120 out of the 129 respondents were in-
cluded in the final analysis, while 115 (non-respondents) did not give 
informed consent and were not included. Missing data analysis was 
performed between the respondents and non-respondents regard-
ing age, gender, baseline BMI and AHI. There were no significant 
differences between respondents and non-respondents with regard 
to mean baseline AHI (21.9 vs 21.7) and mean BMI (27.8 vs 28.6), 
while age (59.1 years (respondents) vs 52.9 years (non-respondents); 
P < .001) and gender (62.5% men / 37.5% women (respondents) vs 
75.2% men / 24.8% women (non-respondents); P < .05) differed 
significantly.
4  | DISCUSSION
This retrospective study of 120 OSA patients treated with OAs fol-
lowing an acoustic pharyngometry protocol showed an overall suc-
cess rate of 86.7% using success criterion 1-3 (≥50% reduction of AHI 
from baseline). When analysing patients with moderate (n = 59) and 
severe (n = 23) OSA separately, the success rates using criterion 1-3 
were 88.1% and 87.0%, respectively, which indicates that the success 
rate for this population was not affected by OSA severity (Figure 1). 
The result of OA treatment following the AP protocol applied in this 
study seems to be superior compared to studies following the standard 
protocol for OA treatment using similar success criteria (≥50% reduc-
tion of AHI from baseline), where success rates of 77% and 69% were 
achieved for patients with moderate and severe OSA respectively in 
one study, and a success rate of 58% for the entire population of mild 
to severe OSA patients in another.35,36 A more recent study describing 
outcomes of standard protocol OA treatment in severe OSA patients 
presented 60% success following success criteria 3.37 The patients in-
cluded who were treated with an effective OA and not a sham device 
(n = 55) had comparable baseline AHI, BMI, occurrence of hyperten-
sion and distribution of men/woman as the patients with severe OSA 
(n = 23) in this study. However, the difference in number of included 
patients should be noted.
The missing data analysis showed that the included patients 
were representative for the population in terms of baseline AHI 
and BMI, while age and gender differed significantly between the 
respondents and non-respondents; that is, the non-respondents 
had an overrepresentation of men and younger individuals. Younger 
age has previously been identified as a predictor for response to 
OA treatment (≥50% reduction of baseline AHI).38 This finding is 
deemed to be a positive bias, indicating that the treatment effect 
for the entire group might be better than that reported for the pa-
tients in our study group. Further, female gender has been shown to 
predict treatment success in one report,39 while it did not in another 
study.38 Based on these reports, it is difficult to draw any conclusion 
as to whether the overrepresentation of women in the study group 
constituted a bias or not.
Reference category
Unadjusted Adjusted
OR 95% CI P OR 95% CI P
AHI baseline 0.98 0.95-1.00 NS - - NS
BMI 0.83 0.75-0.93 **** 0.88 0.78-0.98 **
Gender 1.46 0.69-3.09 NS - - -
Age 0.99 0.95-1.02 NS - - -
No hypertension 3.29 1.33-8.11 *** 2.90 1.03-8.12 **
No CHD 11.57 1.40-95.6 ** - - NS
Total vertical elevation 1.11 0.95-1.28 NS - - -
No diabetes 2.39 0.21-27.15 NS - - -
VOB 1.25 1.00-1.57 * - - NS
HOB 1.00 0.82-1.22 NS - - -
% of max protrusion 0.30 0.05-1.75 NS - - -
Type of OA 0.87 0.40-1.89 NS - - -
Vertical dim. OA 1.00 0.81-1.24 NS - - -
AP min cross-sectional 
area AOP
1.67 0.91-3.06 * - - NS
AP total volume collapse 1.05 1.00-1.10 * 1.07 1.01-1.13 **
Note: Abbreviations: AOP, acoustic optimal position;AP, acoustic pharyngometry; CHD, coronary 
heart disease; CI, confidence interval for OR; HOB, horizontal overjet; OA, oral appliance; OR, 
odds ratio; VOB, vertical overbite.
Prob > chi2 = 0.0010, Pseudo R2 = 0.1183.
****P ≤ .001; ***.001 < P ≤ .01; **.01 < P ≤ .05; *.05 < P ≤ .1. 
TA B L E  3   Logistic regression model for 
the odds of achieving success criterion 
1 after OA treatment (AHI < 5), with 
success criterion 1 as dependent variable 
for the included 120 patients in the study. 
Dependent variable dichotomised as 
0 = AHI ≥ 5, 1 = AHI < 5
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The AP protocol aims for individualisation of OA treatment. 
Standard protocol OA treatment suggests ‘maximal comfortable 
protrusion’, which often results in 50%-80% of maximal protrusive 
range as the target OA position for optimal treatment effect.40,41 
A systematic review investigating clinical practice in OA titration 
found that all included studies describing percentage of maximal 
protrusion reported a mean protrusion exceeding 85%.10 ‘Maximal 
comfortable protrusion’ was not recorded in the present study but 
the mean of 71.7% of maximal protrusion for the OAs indicates 
that the OAs were less protruded than what is commonly applied. 
Regarding individualisation of OA treatment, a recently published 
study investigating target protrusion of OAs after stepwise titration 
with PG registration at each protrusive adjustment found that the 
target protrusion increased with increasing OSA severity, ranging 
from 38.6% to 68.8% of maximal protrusion.42
In a recent systematic review and meta-analysis, several phe-
notypes predicting response to OA treatment were identified.43 
In our study, low BMI and absence of hypertension could predict 
treatment success in analogy to these findings. In addition, we found 
that increased total vertical elevation introduced by the OA could 
significantly predict treatment success. The total increase of verti-
cal interincisal dimension of the OAs ranged from 4 to 12 mm, with 
a mean of 5.6 mm. A recent study identified patients with larger 
overbite as significantly more likely to achieve complete response 
of OA treatment, hypothesising that increased vertical dimensions 
for these patients normalises the intermaxillary space for the tongue 
in the oral cavity.44 However, a general conclusion should not be 
drawn that increased vertical dimension improves the effect of OA 
treatment. The message is that horizontal and vertical individualisa-
tion of the OA position by using AP seems to improve the treatment 
effect. If the vertical dimension plays an important role in OA treat-
ment, it is evident that locating the individualised optimal vertical 
(and protrusive) position would not be possible following standard 
protocol for OA treatment. In addition, presently available standard 
OAs do not allow adjustment of the vertical dimension. Accordingly, 
AP seems to be an efficient way to locate the individualised optimal 
combined vertical and horizontal position of OAs.
The collapsibility of the upper airway, displayed as the reduc-
tion in total volume from the baseline to the collapse registration 
(modified Mueller manoeuvre) measured with AP, correlated signifi-
cantly with OSA severity at baseline, which seems to be logical as 
patients with severe OSA probably have more collapsible upper air-
ways than those with less severe disease. This has also been demon-
strated in previous studies with AP.31,32 In our study, larger minimum 
cross-sectional area and total volume maintained in the AOP, and 
larger AP total volume during collapse, showed indications of being 
predictors of reaching success criterion 1 (AHI < 5) with OA treat-
ment in the unadjusted model. In the adjusted model, however, only 
total volume maintained during collapse registration at baseline re-
mained a significant predictor for reaching success criterion 1. The 
latter finding indicates that a larger total volume maintained during 
collapse registration, indicating a less collapsible airway, increased 
the odds for reaching success criterion 1. Although it should be 
noted the odds ratio was only 1.07 for this prediction, so the clini-
cal benefit of this should be interpreted with caution. Nevertheless, 
based on the above findings, the applicability of AP in OA treatment 
deserves further attention and more in-depth studies, which are cur-
rently underway in our research group.
The occurrence of reported side effects was rather significant 
in this study population, especially for dry mouth (43.9%). However, 
the reported side effects did not exceed that found in other stud-
ies.45,46 When reporting side effects, patients were asked if they 
had experienced any of the listed side effects in association with OA 
treatment. Hence, some patients might have reported the side ef-
fects commonly occurring in the initial phase of OA treatment which 
usually disappear after a relatively short time. Further, other than 
pain/tension in the masticatory muscles, there was no significant 
relationship between side effects and reported usage of the OA, in-
dicating that the side effects did not affect treatment compliance in 
this population.
4.1 | Limitations
The uncertainty of the reproducibility and validity of AP measures is 
a limitation of the technique. The results of the treatment indicate 
that AP improves OA treatment compared to standard OA treat-
ment, when performed by two calibrated and experienced clinicians. 
The current study was, however, not performed with a randomised 
design including a control group, and direct comparison with other 
studies is not possible due the differences in case selection, etc. The 
clinicians performing the AP and the positioning of OAs in this study 
were highly skilled in using the technique, and the results cannot 
directly be extrapolated in the hands of lesser experienced dentists. 
This will require further investigations. There is also an uncertainty 
regarding the reproducibility of the modified Mueller manoeuvre, 
and the fact that the measures are performed awake and in a seated 
position. The rationale for using the modified Mueller manoeuvre 
when demonstrating collapsibility of the upper airway is that this 
technique was previously shown to demonstrate a reduction in 
pharyngeal cross-sectional area in OSA patients, which was not pre-
sent in non-OSA subjects.31,32 As the subjects in above-mentioned 
studies were seated and awake during AP measures, this was applied 
in our protocol as well (Appendix 1). The reproducibility of total lung 
capacity and residual volume has previously been shown to have ac-
ceptable ICC.33
Some of the included patients were diagnosed with OSA some 
years prior to the OA treatment. This means that, in some patients, 
the true AHI at baseline might have been different at the start of OA 
treatment, due to, for example, greater age and changed BMI.4 This 
was possibly the case in three patients where the initial follow-up 
AHI with OA was higher than the baseline AHI. In those patients, a 
new PG recording was performed without the OA and the results 
showed an aggravation of the OSA diagnosis compared to that at the 
referral time. Still, in those three patients, we used the original base-
line diagnosis and AHI in the analyses, and all of them consequently 
     |  9OPSAHL et AL.
became treatment failures, as reported in the results. Nonetheless, 
this uncertainty would in most cases only generate false-negative 
rather than false-positive results, due to the unlikelihood of reduced 
AHI in the absence of intensive lifestyle interventions.47
There is also some uncertainty about using different diagnostic 
devices for baseline and follow-up sleep recordings. All follow-up 
registrations were made with the same type III devices. These de-
vices have previously shown comparable accuracy in diagnosing 
OSA with a type IV device (Embletta®)48 and with PSG.49,50 The type 
III devices used have shown a slight tendency to overestimate AHI 
compared to Embletta® at lower values, when using autoscore,48 
but this would be correctly adjusted as the present type III reports 
were manually scored in this study, and would also, if AHI was over-
estimated, result in false-negative results.
In summary, the present results indicate that OA treatment fol-
lowing an AP protocol provides high treatment success rates in the 
hands of trained clinicians, applying considerable variation in the ver-
tical dimension for OAs, ranging from 4 to 12 mm. Individualisation 
of OA treatment through locating the AOP seems to play a vital role 
in improving the treatment outcome. However, further research to 
investigate the possible health and cost benefits of applying AP in 
OA treatment is needed to broaden the current findings.
5  | CONCLUSION
The AP protocol applied in this study seems to provide a very high 
OA treatment success rate. Further research on the application of 
AP in OA treatment is needed in order to clarify its likely beneficial 
contribution to improving OA therapy.
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APPENDIX 1
Acoustic pharyngometry - A new method to facilitate oral appli-
ance therapy
All patients treated with oral appliances (OAs) at the two dental 
clinics at Tannhelsesenteret Lørenskog and Tannhelsesenteret 
Sogndal between 2013 and 2018 were treated according to the 
following protocol, referred to as an acoustic pharyngometry 
(AP) protocol. This protocol is based upon the standard operat-
ing protocol for acoustic pharyngometry previously described by 
Kamal.25
General information about acoustic pharyngometry examination
1. Patient position: The patient is seated in an upright position on 
a straight-back chair and instructed to maintain a neutral head 
position. The patient's comfort was enabled by positioning the 
chair with its back against a wall, so that their head could 
be supported/stabilised by contact with the wall. The patient 
is instructed to remain still during the examination and to fix 
their eyes on something at the same height on the opposite 
side of the room, thus keeping the head in an unchanged 
horizontal position.
2. Patient considerations: Patients were told to silently pronounce the 
word ‘ooh’ to rest their tongue in a relaxed position on the floor of 
the mouth, and to compress their nostrils (by pinching with thumb 
and forefinger) so as to prevent air from escaping, throughout the 
examination (Eccovision acoustic pharyngometry manual).
3. Wave tube and mouthpiece: The snorkel-like mouthpiece is made 
of rubber and is designed with a flange under the lips to form an 
acoustic seal (Eccovision acoustic pharyngometry manual). Sound 
waves, which are produced by the wave tube, are introduced into 
the oral and pharyngeal cavities via the mouthpiece and reflected 
back to a microphone housed in the wave tube. The wave tube is 
placed horizontally, parallel to the floor (Eccovision acoustic phar-
yngometry manual).
4. The baseline registration: The baseline registration is measured at 
functional residual capacity (FRC). The patient is instructed to 
slowly inhale and exhale, similar to normal breathing. AP data are 
registered at the end of normal expiration.
5. The collapse registration: The collapse registration is measured at 
residual volume (RV). RV is generated using the modified Mueller 
manoeuvre, in which the patient slowly exhales from total lung 
capacity (TLC) to RV. The patient is first informed about the 
modified Mueller manoeuvre and practices it together with the 
clinician, who remains in attendance until after the manoeuvre is 
accomplished. The rationale for using the modified Mueller ma-
noeuvre is that OSA patients have previously been shown to be 
more prone to have a more collapsible airway at RV than subjects 
without OSA.31,51
Figure A1 is an example of AP data for baseline and collapse reg-
istrations displayed in the same graph.
Locating the acoustic optimal position
1. First, baseline and collapse registration are performed when 
biting on the mouthpiece in habitual occlusion to establish 
the baseline values. Because of the thickness of the rubber 
mouthpiece, the baseline registrations are performed with 2 mm 
interincisal distance.
2. The airway metrics system (Figure A2) provides bite jigs with vari-
ous thicknesses and notches on both sides of the jig, allowing the 
clinician to place the patient's mandible in different horizontal 
and vertical positions in a controlled manner (Figure A3). Collapse 
registrations are sequentially performed with the mandible in 
F I G U R E  A 1   An example of acoustic pharyngometry data for baseline and collapse registrations displayed in the same graph. The cross-
sectional area is displayed on the y-axis (Area, cm2) and the distance displayed on the x-axis (Distance, cm), measured from the lips at 0.0 cm 
and 25.0 cm into the upper airway. The column to the right displays the results of the measures, showing the total volume (Volume), the 
mean cross-sectional area (Mean), the minimal cross-sectional area (Minimum) and the distance from the lips to the minimal cross-sectional 
area (Min Dist)
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different horizontal and vertical positions, starting at 50% of max-
imal protrusion and 4 mm interincisal distance. Next, AP measures 
are performed at the same 4 mm interincisal distance, but at both 
increased and reduced protrusion. Further, identical procedures 
are performed with 2 mm incremental increases in interincisal 
distance, until all five interincisal distances, from 4 to 12 mm, are 
investigated. If a trend of reduced upper airway volume with in-
creased interincisal distance is observed, further investigations 
with increased vertical position are not performed. Similarly, if 
increased or decreased protrusion at a fixed interincisal distance 
results in reduced upper airway volume, further investigation 
in the given horizontal direction is not performed. The posi-
tion demonstrating the largest total volume and largest minimal 
cross-sectional area during collapse registration is deemed the 
acoustic optimal position (AOP). If two or more positions show 
similar AP values, the position with the least protrusion is chosen 
due to lesser potential side effects.15 If two positions with equal 
protrusion and different interincisal distances show similar AP 
values, the position with the lowest interincisal distance is cho-
sen, again for better patient comfort, thus hypothetically provid-
ing better compliance with the treatment.
Jaw registration
1. Jaw registration is performed in the AOP using the bite jig 
that provides the corresponding horizontal and vertical position. 
A bite fork and handle are fitted into opposite ends of the 
bite jig, providing stability for the jaw registration material 
(Figure A4). The jaw registration, once cured, ensures that the 
registration is performed in the intended horizontal and vertical 
position.
Delivery and control of oral appliances
1. Upon delivery and at each follow-up of the OA, collapse regis-
trations are performed with the OA in place, first in the AOP, 
and thereafter at a 1 mm protruded, and a 1 mm retruded 
position relative to the AOP. If a trend of greater volume 
and maintenance of minimal cross-sectional is discovered, this 
position is investigated further by protruding/retruding the OA 
with successive 1 mm increments, while performing new col-
lapse-registrations at each horizontal position of the OA. If a 
new AOP is discovered, the OA is adjusted to this position.
F I G U R E  A 2   The airway metrics system displayed, with bite-
jigs with various thicknesses and notches on both sides of the jig, 
allowing the clinician to place the patient's mandible in different 
horizontal and vertical positions in a controlled manner
F I G U R E  A 3   An example of how to use the bite jigs in the 
airway metrics system. This patient's mandible is positioned with 
4 mm interincisal distance and 2 mm protrusion from edge to edge
F I G U R E  A 4   Jaw registration is performed in the AOP using 
the bite jig that provides the corresponding horizontal and vertical 
position, which is 4 mm interincisal distance and 2 mm protrusion 
from edge to edge in this example. A bite fork and handle are fitted 
into opposite ends of the bite jig, providing stability for the jaw 
registration material, which is added in a controlled manner while 
the patient is positioned in the AOP
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2. If, before follow-up, the patient reaches success criterion 1 
(AHI < 5) with the OA in the current AOP, control of the OA with 
AP is not performed.
3. If the patient experiences significant side effects, resulting in com-
pliance-issues, the OA is retruded to a position that is acceptable 
to the patient, and then gradually titrated forward to the previ-
ously determined AOP at subsequent follow-ups.
4. If patients have problems with retention of the OA, or other prob-
lems related to the type of OA, another type of OA is made in the 
same AOP as the current OA.
